Abstract
Background Wastewater-based epidemiology is a promising approach but robust epidemiological models to relate wastewater to community prevalence are lacking. Assessments of SARS-CoV-2 infection rates have relied primarily on convenience sampling, which does not provide reliable estimates of community prevalence because of inherent biases.
Methods From August 2020 to February 2021, we conducted a serial stratified randomized samplings to estimate the prevalence of anti-SARS-CoV-2 antibodies in 3,717 participants, and weekly sampling of community wastewater for SARS-CoV-2 concentrations in Jefferson County, KY. With the use of a Susceptible, Infected, Recovered (SIR)-type model, we obtained longitudinal estimates of prevalence and compared these with wastewater concentration, using regression analysis.
Findings Model analysis revealed significant temporal differences in epidemic peaks; the average incidence rate based on serological sampling in some areas was up to 50% higher than health department rates based on convenience sampling. The model-estimated average prevalence rates correlated well with wastewater (correlation=0·63). In regression analysis, a weekly unit increase in wastewater concentration of SARS-CoV-2 corresponded to an average increase of between 1-1·3 cases of SARS-CoV-2 infection per 100K residents.
Interpretation Publicly available health department incidence rates vastly underestimate true community incidence and wastewater has a high potential to provide robust estimates of community spread of infection.
Evidence before this study Administratively reported clinical case rates of coronavirus disease 2019 (COVID-19) infected individuals are biased due to a wide range of factors from testing access to concerns about missing low and non-symptomatic and self-tested individuals. Wastewater estimates offer an alternative to support community monitoring based on fecal shedding of the virus but are difficult to interpret when compared with the available public health data sets of infection rates. We examined all English literature until February 24, 2022, on Web of Science and PubMed with the terms [“seroprevalence” or “antibody”] AND [“COVID-19” or “SARS-CoV-2”] AND [“wastewater”]. We identified six studies. None of these studies considered randomized COVID-19 community anti-SARS-CoV-2 antibody testing paired with wastewater data.
Added value of this study The study demonstrates how results from serial stratified randomized serological sampling of the community can be used to build a longitudinal model that can interpolate and extrapolate community levels of infection beyond specific testing dates. Such a model correlates well with wastewater concentrations indicating its utility as a surrogate for infection prevalence. The testing data used in the study were collected before wide availability of COVID-19 vaccines and are therefore unique as they are unlikely to include a significant number of false positive results.
Implications of all the available evidence The study demonstrates that convenience sampling obtained data from health department reporting seriously underestimates community-wide prevalence of infection. In contrast, wastewater-based epidemiology may be a faster, cost-effective, and more robust method of estimating the prevalence of viral infections within specific urban areas.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by a contract by the Centers for Disease Control, the Louisville-Jefferson County Metro Government as a component of the Coronavirus Aid, Relief, and Economic Security Act, as well as grants from the James Graham Brown Foundation and the Owsley Brown II Family Foundation. Serology work was also supported in part by the Jewish Heritage Fund and the Center for Predictive Medicine for Biodefense and Emerging Infectious Disease.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
For the seroprevalence and data on COVID-19 infected individuals provided by the LMPHW under a Data Transfer Agreement, the University of Louisville Institutional Review Board approved this as Human Subjects Research (IRB number: 20.0393). For the wastewater, the University of Louisville Institutional Review Board classified this as non-human subjects research (reference #: 717950).
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
↵* Joint first authors
Data Availability
The seroprevalence and wastewater data used in the study can be accessed at https://github.com/cbskust/Seroprevalene.COVID19. The computer code implementing our model-based analysis will be made available immediately following publication. The code will be shared with researchers who provide a methodologically sound proposal approved by GAR and AB. Proposals should be directed to rempala.3{at}osu.edu and aruni.bhatnagar{at}louisville.edu; requesters will need to sign a data access agreement.
